US Patent

US9850246 — Process for making CGRP receptor antagonists

Composition of Matter · Assigned to Merck Sharp and Dohme LLC · Expires 2033-03-13 · 7y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a novel process for making certain CGRP receptor antagonists, specifically piperidinone carboxamide indane and azainane derivatives.

USPTO Abstract

The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.

Drugs covered by this patent

Patent Metadata

Patent number
US9850246
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-03-13
Drug substance claim
Yes
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.